Early stopping rules in oncology: Considerations for clinicians-Reference-Cited by-同舟云学术

Early stopping rules in oncology: Considerations for clinicians

Published:2011-11 Issue:16 Volume:47 Page:2381-2386
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Mukherjee Som D.,Goffin John R.,Taylor Valerie,Anderson Kelly K.,Pond Gregory R.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. National Institute of Health Policy for Data and Safety Monitoring. June 1998. Website: http://grants.nih.gov/grants/guide/notice-files/not98-084.html.

2. Forming your phase III trial’s data and safety monitoring board: a perspective on safety;Wittes;J Investig Med,2004

3. Randomized trials stopped early for benefit: a systematic review;Montori;JAMA,2005

4. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of the NSABP protocol C-08;Allegra;J Clin Oncol,2011

5. De Gramont A, Van Cutsem E, Tabernero J et al. AVANT: Results from a randomized, three arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. 2011 Gastrointestinal Cancers Symposium (ASCO GI). Abstract no. 362. J Clin Oncol 2001: 29 (suppl 4; abstract 362).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Trial Design—A Review—With Emphasis on Acute Intervertebral Disc Herniation;Frontiers in Veterinary Science;2020-09-02

2. The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam;Trials;2020-05-18

3. Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature;Bone Marrow Transplantation;2019-12-10

4. From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs;Seminars in Cancer Biology;2017-08

5. Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial;Trials;2016-07-22